Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Systemic Sclerosis
Latest Information Update: 11 Apr 2025
At a glance
- Drugs Umbilical cord-derived allogeneic mesenchymal stem cell therapy-Vitro Biopharma (Primary)
- Indications Systemic scleroderma
- Focus Adverse reactions
- 08 Apr 2025 Planned End Date changed from 1 Nov 2025 to 1 Nov 2026.
- 08 Apr 2025 Planned primary completion date changed from 1 Nov 2025 to 1 Nov 2026.
- 06 Jan 2022 New trial record